<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01445873</url>
  </required_header>
  <id_info>
    <org_study_id>B1321051</org_study_id>
    <nct_id>NCT01445873</nct_id>
  </id_info>
  <brief_title>Pilot Chart Review Study Of Sitaxentan Sodium (Thelin) In Patients With Pulmonary Arterial Hypertension (PAH)</brief_title>
  <official_title>Non-Interventional (NI) Drug Study Protocol: Three-Country Pilot Study For Retrospective Chart Review Of Effectiveness Of Thelin® (Sitaxsentan) In Patients With Pulmonary Arterial Hypertension (PAH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to develop research methods and corresponding materials for
      a study of the effectiveness of sitaxentan sodium (Thelin) in &quot;real-world&quot; settings; to pilot
      test these methods at three study centers in Europe; and to refine and finalize research
      methods and corresponding materials for possible use in a follow-on, full-scale examination
      of the effectiveness of sitaxentan sodium (Thelin) in &quot;real-world&quot; settings.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At each centre, approximately 12-15 Pulmonary Arterial Hypertension (PAH) consecutive
      patients who have received Thelin and who meet all other study entry criteria.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patterns of Pharmacotherapy With Sitaxentan Sodium (Thelin): Mean Time to Therapy Augmentation</measure>
    <time_frame>Day 1 to Month 6</time_frame>
    <description>Participants still receiving Thelin with evidence of receipt of another PAH-related therapy (eg. bosentan, sildenafil) not previously received during the study period. Mean time in months to therapy augmentation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patterns of Pharmacotherapy With Sitaxentan Sodium (Thelin): Therapy Switching</measure>
    <time_frame>Day 1 to Month 6</time_frame>
    <description>Participants with evidence of discontinuation of Thelin therapy and evidence of receipt of another PAH-related therapy not previously received during the study period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patterns of Pharmacotherapy With Sitaxentan Sodium (Thelin): Therapy Discontinuation</measure>
    <time_frame>Day 1 to Month 6</time_frame>
    <description>Participants were designated as having discontinued Thelin therapy if there was evidence in the medical records that treatment had been terminated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patterns of Pharmacotherapy With Sitaxentan Sodium (Thelin): Therapy Duration</measure>
    <time_frame>Day 1 to Month 6</time_frame>
    <description>Duration of Thelin therapy based on time from index date (Day 1 of treatment) until the date of discontinuation of Thelin therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patterns of Pharmacotherapy With Sitaxentan Sodium (Thelin): Numbers of Therapy-days Dispensed</measure>
    <time_frame>Day 1 to Month 6</time_frame>
    <description>Duration of Thelin therapy from initial receipt until date of discontinuation of thelin therapy or the end of follow-up, whichever occurred first.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patterns of Pharmacotherapy With Sitaxentan Sodium (Thelin): Daily Dosage</measure>
    <time_frame>Day 1 to Month 6</time_frame>
    <description>Daily dosage of Thelin based on information in the medical record for the baseline visit and all follow-up clinic visits.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Use of Other Pulmonary Arterial Hypertension (PAH)-Related Medications</measure>
    <time_frame>Day 1 to Month 6</time_frame>
    <description>Use of PAH-related medications other than Thelin described by class of agent received.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in World Health Organization (WHO) Functional Class of Pulmonary Hypertension</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <description>Class I: no limitation of usual (usl) physical activity (PA); PA does not increase(d) (incr) dyspnea (dys), fatigue (ftg), chest pain (CP), or syncope (syn); Class II: mild limitation of usl PA; no discomfort at rest, but normal PA causes incr dys, ftg, CP, or presyncope (presyn); Class III: marked limitation of PA; no discomfort at rest but &lt; ordinary activity causes incr dys, ftg, CP, or presyn; Class IV: unable to perform any PA at rest; may have signs of right ventricular failure; sys and/or ftg at rest and symptoms are incr by almost any PA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Right Atrial Pressure</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <description>Difference between pre-index and follow-up value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Pulmonary Artery Pressure</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <description>Difference between pre-index and follow-up value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pulmonary Capillary Wedge Pressure</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <description>Difference between pre-index and follow-up value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Left Ventricular End Diastolic Pressure</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <description>Difference between pre-index and follow-up value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pulmonary Vascular Resistance</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <description>Difference between pre-index and follow-up value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Cardiac Output</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <description>Difference between pre-index and follow-up value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Tei Index</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <description>Difference between pre-index and follow-up value. Combined myocardial performance index calculated by adding isovolumic contraction time and isovolumic relaxation time and dividing the resulting sum by ejection time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Tricuspid Regurgitant Velocity</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <description>Difference between pre-index and follow-up value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Total Distance Walked During 6 Minute Walk Test (6MWT)</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <description>6MWT was the distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed. Continuous pulse oximetry was conducted during the test for safety. Difference between pre-index and follow-up value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Borg Dyspnoea Score</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <description>Borg dyspnoea scale is a 10-point scale where following scores stands for severity of dyspnoea: 0 (no breathlessness at all); 0.5 (very very slight [just noticeable]); 1 (very slight); 2 (slight breathlessness); 3 (moderate); 4 (some what severe); 5 (severe breathlessness); 7 (very severe breathlessness); 9 (very very severe [almost maximum] and 10 (maximum). Difference between pre-index and follow-up value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percent of Predicted Peak VO2</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <description>Difference between pre-index and follow-up value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Arterial Hypertension (PAH) Severity and Functional Status: Time to Clinical Worsening</measure>
    <time_frame>Day 1 to Month 6</time_frame>
    <description>Occurrence of any of the following: death, unplanned PAH-related hospitalization, initiation of epoprostenol, arterial septostomy, lung or heart/lung transplantation, ≥15% decrease from baseline in 6 minute walk test, signs/symptoms of right sided heart failure, and/or worsening WHO functional class.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other Pulmonary Arterial Hypertension (PAH)-Related Outcomes: Mortality</measure>
    <time_frame>Day 1 to Month 6</time_frame>
    <description>Number of participants who died during the follow-up period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hospitalizations</measure>
    <time_frame>Day 1 to Month 6</time_frame>
    <description>All hospitalizations during the follow-up period recorded in medical records.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other Pulmonary Arterial Hypertension (PAH)-Related Outcomes: Lung Transplantation</measure>
    <time_frame>Day 1 to Month 6</time_frame>
    <description>Number of participants who received an lung transplant during hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other Pulmonary Arterial Hypertension (PAH)-Related Outcomes: Heart/Lung Transplantation</measure>
    <time_frame>Day 1 to Month 6</time_frame>
    <description>Number of participants who received an heart/lung transplant during hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other Pulmonary Arterial Hypertension (PAH)-Related Outcomes: Atrial Septostomy</measure>
    <time_frame>Day 1 to Month 6</time_frame>
    <description>Number of participants who received an atrial septostomy (balloon or blade) during hospitalization.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">36</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>PAH patients receiving Sitaxentan</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitaxentan sodium</intervention_name>
    <description>Sitaxentan sodium 100 mg / day</description>
    <arm_group_label>PAH patients receiving Sitaxentan</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Pulmonary Arterial Hypertension (PAH) (Idiopathic or secondary to connective
        tissue disease), receiving sitaxentan sodium (Thelin) for treatment of their PAH for at
        least 6 months.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Idiopathic PAH, or PAH secondary to connective tissue disease

          -  Receipt of Thelin for treatment of PAH

          -  6 months of follow-up (except in the event of death) subsequent to initial receipt of
             Thelin

          -  Minimum of one clinic visit documented in the medical record during the 6-month period
             subsequent to initial receipt of Thelin

        Exclusion Criteria:

          -  Participation in any investigational study of Thelin or any other medication for the
             treatment of PAH during the period beginning 6 months prior to initial receipt of
             Thelin and ending 6 months subsequent to such receipt

          -  Receipt of Thelin prior to January 11, 2005 (i.e., the date following the last day on
             which patients could be enrolled in double-blind treatment in STRIDE-1, STRIDE-2,
             and/or STRIDE-6); or

          -  Known contraindications to Thelin therapy (i.e., known hypersensitivity to sitaxsentan
             or any of its excipients; mild-to-severe hepatic impairment [Child-Pugh Class A-C];
             elevated aminotransferases prior to initiation of treatment, defined as aspartate
             aminotransferase [AST] and/or alanine aminotransferase [ALT] &gt;3 times upper limit of
             normal [ULN]; concomitant use of cyclosporin A; lactation)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1321051&amp;StudyName=Pilot%20Chart%20Review%20Study%20Of%20Sitaxentan%20Sodium%20%28Thelin%29%20In%20Patients%20With%20Pulmonary%20Arterial%20Hypertension%20%28PAH%29</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2011</study_first_submitted>
  <study_first_submitted_qc>September 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2011</study_first_posted>
  <results_first_submitted>February 14, 2012</results_first_submitted>
  <results_first_submitted_qc>May 9, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 8, 2012</results_first_posted>
  <last_update_submitted>May 9, 2012</last_update_submitted>
  <last_update_submitted_qc>May 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary arterial hypertension</keyword>
  <keyword>sitaxentan sodium</keyword>
  <keyword>Thelin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitaxsentan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Data for this retrospective non-interventional study were abstracted from the medical records of subjects who met study entry criteria.</recruitment_details>
      <pre_assignment_details>Patterns of treatment with Thelin including duration and daily dosages reflect treatment participants received in clinical practice. Treatment was not specified by the protocol.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sitaxentan (Thelin)</title>
          <description>Duration and dose as prescribed in clinical practice.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sitaxentan (Thelin)</title>
          <description>Duration and dose as prescribed in clinical practice.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>19 to 24 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25 to 30 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>31 to 36 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>37 to 42 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>43 to 48 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>49 to 54 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>55 to 60 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>61 to 66 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>67 to 72 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>73 to 78 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>79 to 84 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>85 to 90 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patterns of Pharmacotherapy With Sitaxentan Sodium (Thelin): Mean Time to Therapy Augmentation</title>
        <description>Participants still receiving Thelin with evidence of receipt of another PAH-related therapy (eg. bosentan, sildenafil) not previously received during the study period. Mean time in months to therapy augmentation.</description>
        <time_frame>Day 1 to Month 6</time_frame>
        <population>Full analysis set (FAS): participants with idiopathic pulmonary arterial hypertension (PAH) or PAH secondary to connective tissue disease, receipt of Thelin for treatment of PAH, 6 months of follow-up (except for death) after initial receipt (IR) of Thelin, and at least 1 clinic visit in medical record during 6-month period after IR of Thelin.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitaxentan (Thelin)</title>
            <description>Duration and dose as prescribed in clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Patterns of Pharmacotherapy With Sitaxentan Sodium (Thelin): Mean Time to Therapy Augmentation</title>
          <description>Participants still receiving Thelin with evidence of receipt of another PAH-related therapy (eg. bosentan, sildenafil) not previously received during the study period. Mean time in months to therapy augmentation.</description>
          <population>Full analysis set (FAS): participants with idiopathic pulmonary arterial hypertension (PAH) or PAH secondary to connective tissue disease, receipt of Thelin for treatment of PAH, 6 months of follow-up (except for death) after initial receipt (IR) of Thelin, and at least 1 clinic visit in medical record during 6-month period after IR of Thelin.</population>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Patterns of Pharmacotherapy With Sitaxentan Sodium (Thelin): Therapy Switching</title>
        <description>Participants with evidence of discontinuation of Thelin therapy and evidence of receipt of another PAH-related therapy not previously received during the study period.</description>
        <time_frame>Day 1 to Month 6</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Sitaxentan (Thelin)</title>
            <description>Duration and dose as prescribed in clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Patterns of Pharmacotherapy With Sitaxentan Sodium (Thelin): Therapy Switching</title>
          <description>Participants with evidence of discontinuation of Thelin therapy and evidence of receipt of another PAH-related therapy not previously received during the study period.</description>
          <population>FAS</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Patterns of Pharmacotherapy With Sitaxentan Sodium (Thelin): Therapy Discontinuation</title>
        <description>Participants were designated as having discontinued Thelin therapy if there was evidence in the medical records that treatment had been terminated.</description>
        <time_frame>Day 1 to Month 6</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Sitaxentan (Thelin)</title>
            <description>Duration and dose as prescribed in clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Patterns of Pharmacotherapy With Sitaxentan Sodium (Thelin): Therapy Discontinuation</title>
          <description>Participants were designated as having discontinued Thelin therapy if there was evidence in the medical records that treatment had been terminated.</description>
          <population>FAS</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Patterns of Pharmacotherapy With Sitaxentan Sodium (Thelin): Therapy Duration</title>
        <description>Duration of Thelin therapy based on time from index date (Day 1 of treatment) until the date of discontinuation of Thelin therapy.</description>
        <time_frame>Day 1 to Month 6</time_frame>
        <population>FAS; participants without evidence of discontinuation of Thelin therapy were censored at the end of follow-up (at 6 months or death if prior to 6 months).</population>
        <group_list>
          <group group_id="O1">
            <title>Sitaxentan (Thelin)</title>
            <description>Duration and dose as prescribed in clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Patterns of Pharmacotherapy With Sitaxentan Sodium (Thelin): Therapy Duration</title>
          <description>Duration of Thelin therapy based on time from index date (Day 1 of treatment) until the date of discontinuation of Thelin therapy.</description>
          <population>FAS; participants without evidence of discontinuation of Thelin therapy were censored at the end of follow-up (at 6 months or death if prior to 6 months).</population>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Patterns of Pharmacotherapy With Sitaxentan Sodium (Thelin): Numbers of Therapy-days Dispensed</title>
        <description>Duration of Thelin therapy from initial receipt until date of discontinuation of thelin therapy or the end of follow-up, whichever occurred first.</description>
        <time_frame>Day 1 to Month 6</time_frame>
        <population>Not analyzed: duration of Thelin therapy as number of therapy days dispensed was not summarized; this measure was reported as duration in months only.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitaxentan (Thelin)</title>
            <description>Duration and dose as prescribed in clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Patterns of Pharmacotherapy With Sitaxentan Sodium (Thelin): Numbers of Therapy-days Dispensed</title>
          <description>Duration of Thelin therapy from initial receipt until date of discontinuation of thelin therapy or the end of follow-up, whichever occurred first.</description>
          <population>Not analyzed: duration of Thelin therapy as number of therapy days dispensed was not summarized; this measure was reported as duration in months only.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Patterns of Pharmacotherapy With Sitaxentan Sodium (Thelin): Daily Dosage</title>
        <description>Daily dosage of Thelin based on information in the medical record for the baseline visit and all follow-up clinic visits.</description>
        <time_frame>Day 1 to Month 6</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Sitaxentan (Thelin)</title>
            <description>Duration and dose as prescribed in clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Patterns of Pharmacotherapy With Sitaxentan Sodium (Thelin): Daily Dosage</title>
          <description>Daily dosage of Thelin based on information in the medical record for the baseline visit and all follow-up clinic visits.</description>
          <population>FAS</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Other Pulmonary Arterial Hypertension (PAH)-Related Medications</title>
        <description>Use of PAH-related medications other than Thelin described by class of agent received.</description>
        <time_frame>Day 1 to Month 6</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Sitaxentan (Thelin)</title>
            <description>Duration and dose as prescribed in clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Other Pulmonary Arterial Hypertension (PAH)-Related Medications</title>
          <description>Use of PAH-related medications other than Thelin described by class of agent received.</description>
          <population>FAS</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anticoagulants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diuretics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium channel blockers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Digoxin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supplemental oxygen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prostanoids</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other endothelin receptor antagonists</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphodiesterase-5 inhibitors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in World Health Organization (WHO) Functional Class of Pulmonary Hypertension</title>
        <description>Class I: no limitation of usual (usl) physical activity (PA); PA does not increase(d) (incr) dyspnea (dys), fatigue (ftg), chest pain (CP), or syncope (syn); Class II: mild limitation of usl PA; no discomfort at rest, but normal PA causes incr dys, ftg, CP, or presyncope (presyn); Class III: marked limitation of PA; no discomfort at rest but &lt; ordinary activity causes incr dys, ftg, CP, or presyn; Class IV: unable to perform any PA at rest; may have signs of right ventricular failure; sys and/or ftg at rest and symptoms are incr by almost any PA.</description>
        <time_frame>Baseline to Month 6</time_frame>
        <population>FAS; N=number of participants with pre-index (prior to Thelin initiation) and ≥ 1 WHO value recorded during follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitaxentan (Thelin)</title>
            <description>Duration and dose as prescribed in clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in World Health Organization (WHO) Functional Class of Pulmonary Hypertension</title>
          <description>Class I: no limitation of usual (usl) physical activity (PA); PA does not increase(d) (incr) dyspnea (dys), fatigue (ftg), chest pain (CP), or syncope (syn); Class II: mild limitation of usl PA; no discomfort at rest, but normal PA causes incr dys, ftg, CP, or presyncope (presyn); Class III: marked limitation of PA; no discomfort at rest but &lt; ordinary activity causes incr dys, ftg, CP, or presyn; Class IV: unable to perform any PA at rest; may have signs of right ventricular failure; sys and/or ftg at rest and symptoms are incr by almost any PA.</description>
          <population>FAS; N=number of participants with pre-index (prior to Thelin initiation) and ≥ 1 WHO value recorded during follow-up.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-index functional class (FC) I to FC I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-index functional class (FC) I to FC II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-index functional class (FC) I to FC III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-index functional class (FC) I to FC IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-index functional class (FC) II to FC I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-index functional class (FC) II to FC II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-index functional class (FC) II to FC III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-index functional class (FC) II to FC IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-index functional class (FC) III to FC I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-index functional class (FC) III to FC II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-index functional class (FC) III to FC III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-index functional class (FC) III to FC IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-index functional class (FC) IV to FC I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-index functional class (FC) IV to FC II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-index functional class (FC) IV to FC III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-index functional class (FC) IV to FC IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Right Atrial Pressure</title>
        <description>Difference between pre-index and follow-up value.</description>
        <time_frame>Baseline to Month 6</time_frame>
        <population>FAS; N=number of participants with pre-index and ≥ 1 value recorded during follow-up period.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitaxentan (Thelin)</title>
            <description>Duration and dose as prescribed in clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Right Atrial Pressure</title>
          <description>Difference between pre-index and follow-up value.</description>
          <population>FAS; N=number of participants with pre-index and ≥ 1 value recorded during follow-up period.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" lower_limit="-3.9" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Pulmonary Artery Pressure</title>
        <description>Difference between pre-index and follow-up value.</description>
        <time_frame>Baseline to Month 6</time_frame>
        <population>Data not analyzed: no participants had pre-index and follow-up values reported for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitaxentan (Thelin)</title>
            <description>Duration and dose as prescribed in clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Pulmonary Artery Pressure</title>
          <description>Difference between pre-index and follow-up value.</description>
          <population>Data not analyzed: no participants had pre-index and follow-up values reported for this outcome measure.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pulmonary Capillary Wedge Pressure</title>
        <description>Difference between pre-index and follow-up value.</description>
        <time_frame>Baseline to Month 6</time_frame>
        <population>FAS; N=number of participants with pre-index and follow-up values.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitaxentan (Thelin)</title>
            <description>Duration and dose as prescribed in clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pulmonary Capillary Wedge Pressure</title>
          <description>Difference between pre-index and follow-up value.</description>
          <population>FAS; N=number of participants with pre-index and follow-up values.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="0.1" upper_limit="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Left Ventricular End Diastolic Pressure</title>
        <description>Difference between pre-index and follow-up value.</description>
        <time_frame>Baseline to Month 6</time_frame>
        <population>Data not analyzed: no participants had pre-index and follow-up values for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitaxentan (Thelin)</title>
            <description>Duration and dose as prescribed in clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Left Ventricular End Diastolic Pressure</title>
          <description>Difference between pre-index and follow-up value.</description>
          <population>Data not analyzed: no participants had pre-index and follow-up values for this outcome measure.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pulmonary Vascular Resistance</title>
        <description>Difference between pre-index and follow-up value.</description>
        <time_frame>Baseline to Month 6</time_frame>
        <population>FAS; N=number of participants with pre-index and follow-up value.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitaxentan (Thelin)</title>
            <description>Duration and dose as prescribed in clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pulmonary Vascular Resistance</title>
          <description>Difference between pre-index and follow-up value.</description>
          <population>FAS; N=number of participants with pre-index and follow-up value.</population>
          <units>Dyn/s/cm5</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-214.3" lower_limit="-419.1" upper_limit="-9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Cardiac Output</title>
        <description>Difference between pre-index and follow-up value.</description>
        <time_frame>Baseline to Month 6</time_frame>
        <population>FAS; N=number of participants with pre-index and follow-up value.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitaxentan (Thelin)</title>
            <description>Duration and dose as prescribed in clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cardiac Output</title>
          <description>Difference between pre-index and follow-up value.</description>
          <population>FAS; N=number of participants with pre-index and follow-up value.</population>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="-1.2" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Tei Index</title>
        <description>Difference between pre-index and follow-up value. Combined myocardial performance index calculated by adding isovolumic contraction time and isovolumic relaxation time and dividing the resulting sum by ejection time.</description>
        <time_frame>Baseline to Month 6</time_frame>
        <population>FAS; N=number of participants with pre-index and ≥ 1 follow-up value.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitaxentan (Thelin)</title>
            <description>Duration and dose as prescribed in clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Tei Index</title>
          <description>Difference between pre-index and follow-up value. Combined myocardial performance index calculated by adding isovolumic contraction time and isovolumic relaxation time and dividing the resulting sum by ejection time.</description>
          <population>FAS; N=number of participants with pre-index and ≥ 1 follow-up value.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-0.3" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Tricuspid Regurgitant Velocity</title>
        <description>Difference between pre-index and follow-up value.</description>
        <time_frame>Baseline to Month 6</time_frame>
        <population>FAS; N=number of participants with pre-index and ≥ 1 follow-up value.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitaxentan (Thelin)</title>
            <description>Duration and dose as prescribed in clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Tricuspid Regurgitant Velocity</title>
          <description>Difference between pre-index and follow-up value.</description>
          <population>FAS; N=number of participants with pre-index and ≥ 1 follow-up value.</population>
          <units>m/sec</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" lower_limit="-0.5" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Total Distance Walked During 6 Minute Walk Test (6MWT)</title>
        <description>6MWT was the distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed. Continuous pulse oximetry was conducted during the test for safety. Difference between pre-index and follow-up value.</description>
        <time_frame>Baseline to Month 6</time_frame>
        <population>FAS; N=number of participants with pre-index and 1 value recorded during follow-up period.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitaxentan (Thelin)</title>
            <description>Duration and dose as prescribed in clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Total Distance Walked During 6 Minute Walk Test (6MWT)</title>
          <description>6MWT was the distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed. Continuous pulse oximetry was conducted during the test for safety. Difference between pre-index and follow-up value.</description>
          <population>FAS; N=number of participants with pre-index and 1 value recorded during follow-up period.</population>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.5" lower_limit="4.7" upper_limit="52.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Borg Dyspnoea Score</title>
        <description>Borg dyspnoea scale is a 10-point scale where following scores stands for severity of dyspnoea: 0 (no breathlessness at all); 0.5 (very very slight [just noticeable]); 1 (very slight); 2 (slight breathlessness); 3 (moderate); 4 (some what severe); 5 (severe breathlessness); 7 (very severe breathlessness); 9 (very very severe [almost maximum] and 10 (maximum). Difference between pre-index and follow-up value.</description>
        <time_frame>Baseline to Month 6</time_frame>
        <population>FAS; N=number of participants with ≥ 1 value recorded during follow-up period.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitaxentan (Thelin)</title>
            <description>Duration and dose as prescribed in clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Borg Dyspnoea Score</title>
          <description>Borg dyspnoea scale is a 10-point scale where following scores stands for severity of dyspnoea: 0 (no breathlessness at all); 0.5 (very very slight [just noticeable]); 1 (very slight); 2 (slight breathlessness); 3 (moderate); 4 (some what severe); 5 (severe breathlessness); 7 (very severe breathlessness); 9 (very very severe [almost maximum] and 10 (maximum). Difference between pre-index and follow-up value.</description>
          <population>FAS; N=number of participants with ≥ 1 value recorded during follow-up period.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" lower_limit="4.0" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Percent of Predicted Peak VO2</title>
        <description>Difference between pre-index and follow-up value.</description>
        <time_frame>Baseline to Month 6</time_frame>
        <population>FAS; N=number of participants with ≥ 1 value recorded during follow-up period.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitaxentan (Thelin)</title>
            <description>Duration and dose as prescribed in clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Percent of Predicted Peak VO2</title>
          <description>Difference between pre-index and follow-up value.</description>
          <population>FAS; N=number of participants with ≥ 1 value recorded during follow-up period.</population>
          <units>percent Vo2</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="0.3" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulmonary Arterial Hypertension (PAH) Severity and Functional Status: Time to Clinical Worsening</title>
        <description>Occurrence of any of the following: death, unplanned PAH-related hospitalization, initiation of epoprostenol, arterial septostomy, lung or heart/lung transplantation, ≥15% decrease from baseline in 6 minute walk test, signs/symptoms of right sided heart failure, and/or worsening WHO functional class.</description>
        <time_frame>Day 1 to Month 6</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Sitaxentan (Thelin)</title>
            <description>Duration and dose as prescribed in clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Pulmonary Arterial Hypertension (PAH) Severity and Functional Status: Time to Clinical Worsening</title>
          <description>Occurrence of any of the following: death, unplanned PAH-related hospitalization, initiation of epoprostenol, arterial septostomy, lung or heart/lung transplantation, ≥15% decrease from baseline in 6 minute walk test, signs/symptoms of right sided heart failure, and/or worsening WHO functional class.</description>
          <population>FAS</population>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Other Pulmonary Arterial Hypertension (PAH)-Related Outcomes: Mortality</title>
        <description>Number of participants who died during the follow-up period.</description>
        <time_frame>Day 1 to Month 6</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Sitaxentan (Thelin)</title>
            <description>Duration and dose as prescribed in clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Other Pulmonary Arterial Hypertension (PAH)-Related Outcomes: Mortality</title>
          <description>Number of participants who died during the follow-up period.</description>
          <population>FAS</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hospitalizations</title>
        <description>All hospitalizations during the follow-up period recorded in medical records.</description>
        <time_frame>Day 1 to Month 6</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Sitaxentan (Thelin)</title>
            <description>Duration and dose as prescribed in clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Hospitalizations</title>
          <description>All hospitalizations during the follow-up period recorded in medical records.</description>
          <population>FAS</population>
          <units>hospitalizations</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.3" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Other Pulmonary Arterial Hypertension (PAH)-Related Outcomes: Lung Transplantation</title>
        <description>Number of participants who received an lung transplant during hospitalization.</description>
        <time_frame>Day 1 to Month 6</time_frame>
        <population>FAS; N=number of participants with hospitalizations during follow-up period.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitaxentan (Thelin)</title>
            <description>Duration and dose as prescribed in clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Other Pulmonary Arterial Hypertension (PAH)-Related Outcomes: Lung Transplantation</title>
          <description>Number of participants who received an lung transplant during hospitalization.</description>
          <population>FAS; N=number of participants with hospitalizations during follow-up period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Other Pulmonary Arterial Hypertension (PAH)-Related Outcomes: Heart/Lung Transplantation</title>
        <description>Number of participants who received an heart/lung transplant during hospitalization.</description>
        <time_frame>Day 1 to Month 6</time_frame>
        <population>FAS; N=number of participants with hospitalizations during follow-up period.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitaxentan (Thelin)</title>
            <description>Duration and dose as prescribed in clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Other Pulmonary Arterial Hypertension (PAH)-Related Outcomes: Heart/Lung Transplantation</title>
          <description>Number of participants who received an heart/lung transplant during hospitalization.</description>
          <population>FAS; N=number of participants with hospitalizations during follow-up period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Other Pulmonary Arterial Hypertension (PAH)-Related Outcomes: Atrial Septostomy</title>
        <description>Number of participants who received an atrial septostomy (balloon or blade) during hospitalization.</description>
        <time_frame>Day 1 to Month 6</time_frame>
        <population>FAS; N=number of participants with hospitalizations during follow-up period.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitaxentan (Thelin)</title>
            <description>Duration and dose as prescribed in clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Other Pulmonary Arterial Hypertension (PAH)-Related Outcomes: Atrial Septostomy</title>
          <description>Number of participants who received an atrial septostomy (balloon or blade) during hospitalization.</description>
          <population>FAS; N=number of participants with hospitalizations during follow-up period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Pre-specified AEs of interest reported in medical records. Other events = emergency hospital admission, worsening PAH, unexplained anemia, alopecia, diarrhea, fatigue, obstipation, loss of appetite, gastric pain, numerous defecation, INH out of range, cardial decompensation, joint pain, pre-syncope, infection of IV line with need of explanation.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sitaxentan (Thelin)</title>
          <description>Duration and dose as prescribed in clinical practice.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Pre-specified events</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Peripheral edema</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Other events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

